New PET scan tracer could spot breast cancer better

NCT ID NCT03863457

Recruiting now Diagnosis Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study is testing a new radioactive tracer called [18F]F-GLN for PET/CT scans in people with breast cancer. The goal is to see how well this tracer highlights tumors and to gather safety information. Up to 40 adults with known or suspected breast cancer will receive one injection of the tracer and undergo imaging. The results will not be used to guide treatment decisions, but may help develop better ways to detect and understand breast cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]F-GLN (a radioactive tracer for PET/CT imaging)
What this could lead to: If successful, this could lead to a new imaging method to better detect and characterize breast cancer subtypes, potentially guiding more personalized treatment.
What could go wrong: This is a very early, small pilot study (40 people) focused on imaging, not treatment. The tracer may not provide clear or useful images, and results may not apply to all breast cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.